Menu

Home / Guides / Foundayo vs. Zepbound

Same maker. Different medicines.

Foundayo vs. Zepbound (2026): A Daily Pill or a Weekly Shot?

By the NexLife Medical Team · Medically reviewed by Adam Kennah, MD (NPI 1144260043) · Updated

Foundayo (orforglipron) is a daily pill and Zepbound (tirzepatide) a weekly shot, and your routine, your health and how you pay usually decide which fits. Self-pay, Foundayo is $149 to $349 a month and Zepbound $299 to $699 (checked November 15, 2026). Both prices depend on your dose and, at higher doses, on refilling within 45 days. NexLife offers neither; its providers prescribe compounded tirzepatide, not FDA-approved, at $115 a month on the 12-month plan or $129 month to month.

  • Foundayo: one tablet a day, with or without food
  • Zepbound: one shot a week, any time of day
  • Self-pay: Foundayo $149 to $349; Zepbound $299 to $699
Published by NexLifeLegitScript-certified
NexLifeSame price at every dose
Illustration of a compounded tirzepatide vial

$115/mo on a 12-month plan, all-inclusive, same price at every dose

Or $129/mo month to month

Compounded tirzepatide is a weekly shot, not Foundayo or Zepbound. Brand-name Zepbound: $299 to $699 a month, by dose and refill timing.

Check my eligibility

About 3 minutes of health questions · No insurance needed · Not prescribed? No charge for medication

See all 4 plans and what a year costs
Compounded tirzepatide, all in, the same price at every dose
PlanPer month12 months at this rate
12-month Most savings$115$1,380
6-month$119$1,428
3-month$125$1,500
Month to month$129$1,548

Month to month costs $168 more over 12 months than the 12-month plan. Plans renew until you cancel. Month to month is billed monthly; the 3-, 6- and 12-month plans are paid upfront at checkout: $375, $714 or $1,380 for tirzepatide.

Price Match Guarantee†. Paying less elsewhere? We match your regular monthly price. How it works

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026)LegitScript-certified

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. The vial shown is an illustration. Always use the strength on your pharmacy’s label.

  • Licensed U.S. providers
  • LegitScript certified
  • Free expedited shipping
  • HSA, FSA, Affirm, Klarna, Afterpay
  • 24/7 support, real people
  • Filled by Absolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA)

Compounded tirzepatide isn’t FDA-approved, isn’t Foundayo or Zepbound, and wasn’t studied in their trials. A licensed provider prescribes it only when it offers a significant difference for you.

At a glance

Foundayo vs Zepbound at a glance: cost, weight loss and side effects

Foundayo vs. Zepbound, the short answer: the difference, self-pay prices, trial results, side effects, Medicare and NexLife, from both labels, LillyDirect and Medicare.gov, read November 1, 2026, with NexLife’s prices as of November 5, 2026
QuestionAnswer
What’s the difference?Foundayo (orforglipron) is a daily pill. Zepbound (tirzepatide) is a weekly shot. Both are Lilly medicines for weight loss in adults.
Which costs less, self-pay?Foundayo: $149 to $299 a month with refills within 45 days. Zepbound: $299 at 2.5 mg, $399 at 5 mg, $449 at 7.5 to 15 mg with a refill within 45 days, or $499 to $699 without (checked Nov. 15, 2026).
Which lost more weight in trials?In separate 72-week trials, not head to head: 11.1% on average on Foundayo 17.2 mg (2.1% on placebo), 20.9% on Zepbound 15 mg (3.1% on placebo), their labels report.
Side effects?Mostly stomach-related, both labels say. At the top doses, 35% on Foundayo and 28% on Zepbound reported nausea (10% and 8% on placebo).
Does Medicare cover them?If you have Part D and qualify, the GLP-1 Bridge charges $50 a month for Foundayo or the Zepbound KwikPen, with prior authorization, from July 1, 2026 to December 31, 2027.
Where does NexLife fit?It offers neither. Its providers prescribe compounded tirzepatide, a weekly shot that isn’t FDA-approved: $115 a month on the 12-month plan or $129 month to month, at every dose.

From the Foundayo and Zepbound labels, LillyDirect and Medicare.gov, read November 1, 2026. Foundayo’s 2.5 and 5.5 mg prices are reduced only through December 31, 2026.

  1. Tell us about you About 3 minutes of health questions
  2. A licensed provider decides You’re prescribed only if it’s right for you
  3. Your partner pharmacy ships Usually within 1 to 2 business days, free

Key takeaways

  • Pill or shot: self-pay, daily Foundayo is $149 to $349 a month; weekly Zepbound $299 to $699 (checked Nov. 15, 2026).
  • Two Lilly medicines. Foundayo (orforglipron) was approved April 1, 2026; Zepbound is also approved for moderate to severe sleep apnea with obesity.
  • Foundayo’s reduced prices: $149 at 2.5 mg and $199 at 5.5 mg run only through December 31, 2026.
  • Zepbound’s $449 at 7.5 to 15 mg needs a refill within 45 days, or it’s $499 to $699.
  • In separate 72-week trials, average weight loss was 11.1% on Foundayo 17.2 mg and 20.9% on Zepbound 15 mg, their labels report.
  • NexLife offers neither. Its providers prescribe compounded tirzepatide, a weekly shot that isn’t FDA-approved: $115 a month on the 12-month plan.

At a glance

How do Foundayo and Zepbound compare?

Foundayo (orforglipron) is a daily pill and Zepbound (tirzepatide) a weekly shot, both Lilly medicines for weight loss in adults; Foundayo was approved April 1, 2026. Self-pay, Foundayo is $149 to $349 a month and Zepbound $299 to $699 (checked Nov. 15, 2026). Here’s each one from its FDA label and Lilly’s prices.

From the Foundayo prescribing information (revised July 2026), the Zepbound prescribing information (revised August 2026), LillyDirect and Medicare.gov, all read November 1, 2026; approval dates from the FDA’s Drugs@FDA data and its sleep apnea news release. A Foundayo month is 30 days; a Zepbound month is 28 days.
FoundayoZepbound
MedicineOrforglipron, a GLP-1 receptor agonistTirzepatide, a GIP and GLP-1 receptor agonist
Form and scheduleA tablet by mouth, once a dayA shot under the skin, once a week
How you take itthe labelWith or without food; swallowed whole; never more than one tablet a dayAny time of day, with or without meals, in the belly or thigh, or the back of the upper arm if someone else injects
Comes asBottles of 30 tablets: 0.8, 2.5, 5.5, 9, 14.5 or 17.2 mgA KwikPen (4 weekly doses), vials or single-dose pens: 2.5 to 15 mg
Dose stepsthe label0.8 mg for at least 30 days, then 2.5 and 5.5 mg; then 9, 14.5 or 17.2 mg, at least 30 days each, by response2.5 mg for 4 weeks, then 5 mg; then up in 2.5 mg steps, at least 4 weeks each; long term at 5, 10 or 15 mg
FDA-approved foradultsWeight loss and keeping it off, with obesity, or overweight and a weight-related condition. Approved April 1, 2026The same weight-loss use, plus moderate to severe obstructive sleep apnea with obesity. Approved November 8, 2023 (sleep apnea: December 20, 2024)
Half-lifetime for blood levels to halveAbout 29 to 49 hoursAbout 5 to 6 days
Self-pay, a monthLillyDirect, checked Nov. 12, 2026$149 to $299; 14.5 and 17.2 mg keep $299 only with a refill within 45 days, otherwise $349$299 at 2.5 mg, $399 at 5 mg; $449 at 7.5 to 15 mg only with a refill within 45 days, otherwise $499 at 7.5 mg or $699 at 10 to 15 mg
With commercial insuranceif your plan covers itSavings card: as low as $25 a monthSavings card for single-dose pens: as low as $25 a month
Medicare, 2026–2027if you qualifyGLP-1 Bridge: $50 a monthGLP-1 Bridge: $50 a month, KwikPen only
Boxed warningRisk of thyroid C-cell tumors. Orforglipron isn’t active in rats or mice and caused no tumors in themRisk of thyroid C-cell tumors. Tirzepatide caused them in rats
Birth control pillsSwitch to a non-pill method, or add a barrier one, for 30 days after starting and after each dose increaseThe same, for 4 weeks after starting and after each dose increase

NexLife Price Match Guarantee†. Already on compounded tirzepatide with another licensed provider, and paying less? We match your regular monthly price. How it works

Swipe the table sideways to see every column.

From the Foundayo prescribing information (revised July 2026), the Zepbound prescribing information (revised August 2026), LillyDirect and Medicare.gov, all read November 1, 2026; approval dates from the FDA’s Drugs@FDA data and its sleep apnea news release. A Foundayo month is 30 days; a Zepbound month is 28 days.

Which fits you

Foundayo or Zepbound: which fits your life?

Mostly your routine, your health and how you pay. Here’s what the labels and prices point to.

  • If you’d rather not inject

    Foundayo is a tablet. Zepbound is a weekly shot, from a KwikPen, a vial or a single-dose pen.

  • If you have sleep apnea

    Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity. Foundayo’s approval covers weight only.

  • If you’d rather dose once a week

    Zepbound is one shot a week, at any time of day. A missed dose can still be taken within 4 days. Foundayo is one tablet every day.

  • If you take other medicines

    Both slow stomach emptying, which can affect pills you take. Foundayo’s label also caps it at 9 mg with strong CYP3A4 inhibitors and limits simvastatin to 20 mg.

  • If cost decides it

    Self-pay, Foundayo tops out at $299 a month with refills within 45 days, where Zepbound starts. Zepbound’s 7.5 to 15 mg doses are $449 only with a refill within 45 days. Otherwise, they’re $499 at 7.5 mg or $699 at 10 to 15 mg.

  • If you have Medicare

    The GLP-1 Bridge covers either for $50 a month if you qualify, Zepbound only as the KwikPen. It isn’t open to people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease. Their Part D plan might still cover a GLP-1, Medicare.gov says.

“Administer ZEPBOUND once weekly at any time of day, with or without meals.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026

Your provider decides which medicine fits you, after reviewing your health history and the other medicines you take.

Step by step

How do you choose between Foundayo and Zepbound?

Your routine, your health and how you pay usually decide it. Work through them in this order, ending with your provider.

  1. Choose a pill or a shot. Foundayo is one tablet a day, with or without food, swallowed whole. Zepbound is one shot a week, at any time of day, from a KwikPen, a vial or a single-dose pen.
  2. Check what each is approved for. Both are approved for weight loss in adults. Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity; Foundayo’s approval covers weight only. Both carry a boxed warning about thyroid C-cell tumors.
  3. List your other medicines. Both slow stomach emptying, which can affect pills you take. With birth control pills, both labels advise a non-pill or barrier method after starting and after each dose increase: 30 days for Foundayo, 4 weeks for Zepbound.
  4. Compare the trial results. Neither label reports a trial comparing them. In separate 72-week trials (ATTAIN-1 and SURMOUNT-1), average weight loss was 11.1% on Foundayo 17.2 mg and 20.9% on Zepbound 15 mg, against 2.1% and 3.1% on placebo. Averages aren’t promises.
  5. Compare price and coverage. Self-pay, Foundayo is $149 to $349 a month and Zepbound $299 to $699, by dose and by whether you refill within 45 days. On Medicare’s Bridge, Foundayo or the Zepbound KwikPen is $50 a month if you qualify.
  6. Let your provider decide. Your provider decides which fits, after reviewing your history and medicines. Switching is a new prescription; don’t take them together. On the Bridge, your prior authorization stays valid only if you don’t change GLP-1s.

Prices were checked Nov. 15, 2026; NexLife offers neither medicine, and your provider decides which one fits you.

How they work

How do Foundayo and Zepbound work?

Both act on GLP-1, a hormone signal that helps regulate appetite, and Zepbound (tirzepatide) acts on GIP too. Foundayo (orforglipron) is a pill you swallow every day; Zepbound is a shot injected once a week. Both are Lilly medicines for weight loss in adults.

Foundayo contains orforglipron, a GLP-1 receptor agonist you swallow. GLP-1 helps regulate appetite, and Foundayo lowers how much you eat, likely by lowering appetite, its label says. It peaks 4 to 8 hours after a dose and reaches a steady level after about a week of daily doses.

Zepbound contains tirzepatide, which acts on two receptors, GIP and GLP-1. Its label notes that studies outside people suggest the GIP part may add to the control of food intake. One shot lasts the week: tirzepatide’s half-life is about 5 to 6 days.

Both slow stomach emptying, which can change how other pills you take are absorbed. Don’t take them together: both labels say using either with another GLP-1 receptor agonist is not recommended.

“Coadministration with other tirzepatide-containing products or with any GLP-1 receptor agonist is not recommended.”

Eli Lilly and Company, Zepbound (tirzepatide) prescribing information, revised August 2026

Is there a tirzepatide pill?

No. The FDA’s Drugs@FDA data list tirzepatide only as injections, Zepbound and Mounjaro (checked November 1, 2026). Foundayo is a pill, but it’s orforglipron, a different medicine. Compounded tablets sold online aren’t FDA-approved and aren’t Foundayo. More: GLP-1 pills vs. injections.

Results

What did the trials show for Foundayo and Zepbound?

Each label reports its own 72-week, placebo-controlled trial: average weight loss was 11.1% on Foundayo 17.2 mg and 20.9% on Zepbound 15 mg (2.1% and 3.1% on placebo). The trials were separate, with different people and dose schedules, so their results can’t be compared head to head.

Not head to head: two separate trials. Figures from each label’s results table, read November 1, 2026; trial names from ClinicalTrials.gov (NCT05869903 and NCT04184622). Both labels count everyone who was randomized, whether or not they finished. These trials studied orforglipron, the medicine in FDA-approved Foundayo, and FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Foundayo (ATTAIN-1)Zepbound (SURMOUNT-1)
Reported inFoundayo label, Trial 1 (revised July 2026)Zepbound label, Study 1 (revised August 2026)
Who took part3,127 adults with obesity, or overweight and a weight-related condition, without type 2 diabetes; average BMI 372,539 adults with the same entry rules, without type 2 diabetes; average BMI 38
Length72 weeks72 weeks
Doses tested5.5, 9 or 17.2 mg a day (Foundayo-equivalent doses of the investigational formulation the trial used; ClinicalTrials.gov lists 6, 12 and 36 mg)5, 10 or 15 mg a week
Average weight losscounting everyone who started11.1% on 17.2 mg 8.3% on 9 mg, 7.4% on 5.5 mg; placebo 2.1%20.9% on 15 mg 19.5% on 10 mg, 15.0% on 5 mg; placebo 3.1%
Lost at least 5%top dose71.5% (26.8% on placebo)90.9% (34.5% on placebo)
Lost at least 15%top dose35.9% (6% on placebo)70.6% (8.8% on placebo)

Swipe the table sideways to see every column.

Not head to head: two separate trials. Figures from each label’s results table, read November 1, 2026; trial names from ClinicalTrials.gov (NCT05869903 and NCT04184622). Both labels count everyone who was randomized, whether or not they finished. These trials studied orforglipron, the medicine in FDA-approved Foundayo, and FDA-approved Zepbound; compounded tirzepatide wasn’t studied.

With type 2 diabetes, average losses were smaller. Each label reports a second 72-week trial: 9.6% on Foundayo 17.2 mg (2.5% on placebo) and 14.7% on Zepbound 15 mg (3.2% on placebo).

These trials studied orforglipron, the medicine in FDA-approved Foundayo, and FDA-approved Zepbound; compounded tirzepatide wasn’t studied.

Side effects

How do the side effects of Foundayo and Zepbound compare?

The side effects of Foundayo and Zepbound are mostly stomach-related, both labels say. Here are the top-dose rates from each label’s own trials, with placebo for comparison.

Placebo in parentheses. Selected rows: Foundayo’s table also lists headache, 9% (7%); Zepbound’s lists allergic reactions, 5% (3%), dizziness, 4% (2%), and low blood pressure, 2% (0%). Each label pools its two placebo-controlled weight trials, up to 72 weeks; the trials were separate, not head to head. These trials studied orforglipron, the medicine in FDA-approved Foundayo, and FDA-approved Zepbound; compounded tirzepatide wasn’t studied.
Side effectFoundayo 17.2 mgZepbound 15 mg
Nausea35% (10%)28% (8%)
Diarrhea25% (11%)23% (8%)
Vomiting24% (4%)13% (2%)
Constipation24% (9%)11% (5%)
Belly painabdominal pain14% (7%)10% (5%)
Indigestiondyspepsia13% (4%)10% (4%)
Tirednessfatigue9% (4%)7% (3%)
Belching8% (1%)5% (1%)
Bloatingabdominal distension8% (3%)4% (2%)
Heartburnreflux (GERD)7% (2%)5% (2%)
Hair loss5% (2%)5% (1%)
Injection site reactionsNot applicable: a pill8% (2%)
Stopped because of side effects10% (3%)6.7% (3.4%)

Placebo in parentheses. Selected rows: Foundayo’s table also lists headache, 9% (7%); Zepbound’s lists allergic reactions, 5% (3%), dizziness, 4% (2%), and low blood pressure, 2% (0%). Each label pools its two placebo-controlled weight trials, up to 72 weeks; the trials were separate, not head to head. These trials studied orforglipron, the medicine in FDA-approved Foundayo, and FDA-approved Zepbound; compounded tirzepatide wasn’t studied.

Mostly early, mostly the stomach. Both labels say nausea, vomiting and diarrhea were most common while the dose was rising, then eased over time.

Both carry a boxed warning about thyroid C-cell tumors. Don’t take either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). Tirzepatide caused these tumors in rats; Foundayo’s label says orforglipron isn’t active in rats or mice and caused no tumors in them.

  • Serious risks on both labels: pancreatitis, gallbladder disease, low blood sugar with insulin or a sulfonylurea, kidney injury from dehydration, severe stomach reactions, serious allergic reactions, eye problems in type 2 diabetes, and breathing in stomach contents under anesthesia or deep sedation.
  • New for both, Nov. 9, 2026: the FDA now requires every GLP-1 medicine’s label, Foundayo’s and Zepbound’s included, to warn of a possible risk of NAION, a rare eye condition that can cause sudden vision loss in one eye. Call your provider right away if that happens (FDA).
  • Never share a Zepbound KwikPen, even with a new needle.
  • Pregnancy: both labels say to stop when a pregnancy is found. Foundayo’s advises against breastfeeding while you take it.
  • Call your provider right away for severe stomach pain that won’t go away, which can mean pancreatitis, or for vomiting or diarrhea that won’t stop. Get emergency help for swelling of your face or throat, or trouble breathing.
  • Report a side effect to your provider, or to the FDA at 1-800-FDA-1088.

Cost

What do Foundayo and Zepbound cost?

Self-pay at LillyDirect, Foundayo is $149 to $299 a month with refills within 45 days, and Zepbound is $299 to $699, by dose and refill timing (checked Nov. 15, 2026). Foundayo’s $149 at 2.5 mg and $199 at 5.5 mg run only through December 31, 2026. Here’s every dose, and what a year costs.

LillyDirect’s self-pay prices and Lilly’s Foundayo and Zepbound terms, checked Nov. 12, 2026, for the medicine alone. A Foundayo month is 30 days; a Zepbound month is 28 days of KwikPen or vials, with needles or syringes bought separately.
DoseA month, refilled within 45 daysWithout a refill within 45 daysGood to know
Foundayo 0.8 mgstarting dose$149$149At least 30 days, then 2.5 mg
Foundayo 2.5 mg$149$149Reduced through December 31, 2026; Lilly’s regular price is $199
Foundayo 5.5 mg$199$199Reduced through December 31, 2026; Lilly’s regular price is $299
Foundayo 9 mg$299$299
Foundayo 14.5 or 17.2 mg$299$349The $299 offer needs a refill within 45 days of your last delivery
Zepbound 2.5 mgstarting dose$299$2994 weeks, then 5 mg; not approved as a long-term dose
Zepbound 5 mg$399$399
Zepbound 7.5 mg$449$499$449 is the 7.5 to 15 mg price only with a refill within 45 days of your last delivery; otherwise $499 at 7.5 mg or $699 at 10 to 15 mg
Zepbound 10, 12.5 or 15 mg$449$699$449 is the 7.5 to 15 mg price only with a refill within 45 days of your last delivery; otherwise $499 at 7.5 mg or $699 at 10 to 15 mg

LillyDirect’s self-pay prices and Lilly’s Foundayo and Zepbound terms, checked Nov. 12, 2026, for the medicine alone. A Foundayo month is 30 days; a Zepbound month is 28 days of KwikPen or vials, with needles or syringes bought separately.

A year at the higher doses. Foundayo at 9 mg, or at 14.5 or 17.2 mg refilled within 45 days, is 12 fills of $299: $3,588. Zepbound is 13 fills a year: $5,187 at 5 mg. At 7.5 to 15 mg, it’s $5,837 if every refill comes within 45 days. At the regular prices, it’s $6,487 (7.5 mg) to $9,087 (10 to 15 mg).

With insurance or Medicare. If your commercial plan covers them, Lilly’s savings cards can bring Foundayo, or Zepbound single-dose pens, to as little as $25 a month. Government plans are excluded, and the cards say they end December 31, 2026. With Medicare Part D, the GLP-1 Bridge charges $50 a month for Foundayo or the Zepbound KwikPen, if you qualify, through December 31, 2027.

List price. Lilly lists Foundayo at $649 for a 30-day supply, a bottle of 30 tablets, at every strength (its price disclosure, read Nov. 15, 2026). The self-pay prices above are what Lilly charges people who pay it directly.

More: Foundayo price and doses, Zepbound cost without insurance and who qualifies for Medicare’s Bridge.

Switching

Can you switch from Zepbound to Foundayo, or back?

Yes, with a new prescription. Your provider decides when, and at what dose.

  1. A new prescription

    Moving from Zepbound to Foundayo, or back, means a new prescription. Your provider decides when, and at what dose; neither label converts one medicine’s doses into the other’s.

  2. Not both at once

    Both labels say using either with another GLP-1 receptor agonist is not recommended.

  3. Each starts low

    For new patients, Foundayo’s label starts at 0.8 mg for at least 30 days, and Zepbound’s at 2.5 mg for 4 weeks. Neither label covers switching; your provider sets your first dose.

  4. Birth control pills

    Both labels advise a non-pill or barrier method after starting and after each dose increase: 30 days for Foundayo, 4 weeks for Zepbound.

  5. Medicare’s Bridge

    Medicare.gov says your Bridge prior authorization stays valid through December 31, 2027, unless you change GLP-1s.

“Your prior authorization is valid (including for refills and dose changes) through December 31, 2027, unless you change GLP-1s.”

Centers for Medicare & Medicaid Services, Weight loss drugs

The price side of a switch. With refills within 45 days, Foundayo’s self-pay prices sit at or below Zepbound’s lowest. Foundayo is $149 to $299 a month; Zepbound’s starting dose alone is $299 (checked Nov. 15, 2026).

At NexLife

Prefer a weekly shot at one price? Compounded tirzepatide at NexLife

NexLife doesn’t offer Foundayo or Zepbound. Its providers prescribe compounded tirzepatide, a different option: a weekly shot that isn’t FDA-approved, at one price at every dose.

The details
Compounded tirzepatide$115 a month on the 12-month plan, $119 on 6 months, $125 on 3 months or $129 month to month
What it isA weekly shot that a state-licensed partner pharmacy prepares for your prescription. It isn’t FDA-approved, it isn’t Zepbound or Foundayo, and it wasn’t studied in their trials.
Same at every doseNo membership fee, and nothing extra when your dose goes up. Zepbound’s self-pay price climbs from $299 at 2.5 mg to $449 at 7.5 to 15 mg. The $449 needs a refill within 45 days; otherwise it’s $499 at 7.5 mg or $699 at 10 to 15 mg.
IncludedA licensed provider who follows your dose, the medication, a nutrition plan, a 1:1 coaching call, free expedited shipping and real people 24/7.
Who fills itAbsolute Pharmacy (Lutz, FL) or Boudreaux’s New Drug Store (Lake Charles, LA), state-licensed 503A partner pharmacies. Questions come to us, not the pharmacy.
How you startAbout 3 minutes of health questions online. A licensed provider reviews them online and prescribes only if it’s right for you.
Ways to payAn HSA or FSA card (NexLife provides a letter of medical necessity), or Affirm, Klarna or Afterpay at checkout. With Medicare, you can pay yourself.
Price Match Guarantee†Paying less for compounded tirzepatide or semaglutide with another licensed provider? We match your regular monthly price, with a receipt from the last 60 days. It doesn’t cover LillyDirect or insurance purchases.

Against the market: month to month, $129 is $156 under the $285 median of the 25 compounded tirzepatide programs that publish a month-to-month price in our GLP-1 price index (checked Nov. 15, 2026).

Who’s behind it: NexLife’s medical director is Adam Kennah, MD, board-certified in emergency medicine by the American Board of Emergency Medicine. Call or text (949) 818-8000, any time.

Already on Zepbound? See switching from Zepbound to compounded tirzepatide, and what it costs.

Compounded tirzepatide isn’t FDA-approved, isn’t Foundayo or Zepbound, and a licensed provider prescribes it only when it offers a significant difference for you.

Vial math

How many units is your tirzepatide dose?

Your tirzepatide dose in units depends on your vial’s strength. Here are the label’s doses at one example strength, with the math to check your own.

Tirzepatide doses on Zepbound’s label, with the volume and units on a U-100 syringe at an example strength of 25 mg per mL; your vial’s label decides
DosemL at 25 mg/mLUnits (U-100)On the label
2.5 mg0.1 mL10 unitsStarting dose, for 4 weeks
5 mg0.2 mL20 unitsA maintenance dose
7.5 mg0.3 mL30 unitsA step up
10 mg0.4 mL40 unitsA maintenance dose
12.5 mg0.5 mL50 unitsA step up
15 mg0.6 mL60 unitsThe maximum, and a maintenance dose

The math: mL = dose ÷ strength (mg per mL), and units = mL × 100. At 25 mg/mL, 10 mg is 10 ÷ 25 = 0.4 mL, or 40 units.

25 mg per mL is an example only: it’s the strength of the 15 mg multi-dose vial on Zepbound’s label (15 mg per 0.6 mL). Read the strength on your own vial’s label; your provider sets your dose, in steps at least 4 weeks apart. Every step: the tirzepatide dosage chart. Or enter your own vial’s strength in the tirzepatide dosage calculator.

Loved by our members

Real stories from NexLife members about their care and service.

A selection of 5-star reviews from Trustpilot, quoted in full as written. Results vary from person to person, and weight loss isn’t guaranteed.

★★★★★TrustScore 4.8 out of 5 on Trustpilot407 reviews as of Nov. 15, 2026 · Read them all ↗

  • ★★★★★Read on Trustpilot ↗

    “So happy with NexLife. Communication has been great, I’m recommending them to all my friends.”

    April

  • ★★★★★Read on Trustpilot ↗

    “Excellent visit. Dr. Kennah was very knowledgeable and helpful and answered all my questions.”

    Ethan B.

  • ★★★★★Read on Trustpilot ↗

    “That’s a real site with good prices and plans!”

    Estefany L.

  • ★★★★★Read on Trustpilot ↗

    “Affordable, quick and easy. They could not have made it a smoother less stressful experience.”

    Andisheh K.

  • ★★★★★Read on Trustpilot ↗

    “Great communication. Easy to work with. They work to set you up for success.”

    Anthony C.

  • ★★★★★Read on Trustpilot ↗

    “Fast delivery and easy to get a hold of when needing to talk with someone!”

    Browneyes

  • ★★★★★Read on Trustpilot ↗

    “Fast service great communication!! Willing to work with you!”

    Bon

  • ★★★★★Read on Trustpilot ↗

    “Great service and excellent communication!”

    Gabrielle D.

  • ★★★★★Read on Trustpilot ↗

    “Easy and pricing not bad! Customer service was helpful in answering my questions.”

    Lyndy T.

  • ★★★★★Read on Trustpilot ↗

    “Good experience, great team”

    Mai S.

  • ★★★★★Read on Trustpilot ↗

    “Great communciation and was fast and reliable”

    Kiki

  • ★★★★★Read on Trustpilot ↗

    “Very happy so far”

    Tammy E.

Names are shortened for privacy. Reviews are members’ opinions, not medical advice.

What does NexLife cost?
One flat price at every dose.

No membership fee. Provider care, a nutrition plan, coaching and shipping are included. Paying less with another licensed provider? We match your regular monthly price.†

Illustration of a compounded tirzepatide vialGIP + GLP-1

12-month plan $115/mo

Tirzepatide

Weekly and dual-action. Care, coaching and shipping included. On a 12-month plan, $1,380 paid upfront; $129/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

Illustration of a compounded semaglutide vialGLP-1

12-month plan $95/mo

Semaglutide

Weekly GLP-1. Care, coaching and shipping included. On a 12-month plan, $1,140 paid upfront; $109/mo month to month, billed monthly.

Check my eligibility

Compounded, not FDA-approved · Not prescribed? No charge for medication

TrustScore 4.8 out of 5 on Trustpilot 407 reviews as of Nov. 15, 2026 · Read them all ↗

Compounded, not FDA-approved. A licensed provider prescribes it only when it offers a significant difference for you. Vials shown are illustrations. Always use the strength on your pharmacy’s label. Every plan and price · Price Match Guarantee† terms

The NexLife Price Match Guarantee†

Paying less elsewhere?
Keep your price. Upgrade your care.

Already on compounded tirzepatide or semaglutide? Pay less with another licensed U.S. telehealth provider or clinic, and we match your regular monthly price for as long as your plan stays active.† Plus a provider who follows your dose, a nutrition plan, a coaching call and real people 24/7.

  1. 1Send a receipt from the last 60 days
  2. 2A NexLife provider reviews your prescription
  3. 3Pay your matched price, at every dose
Switch and keep my price

Locked while your plan is activeSame price at every doseNo membership fee

†Terms: see the Price Match Guarantee† details below. Compounded medications aren’t FDA-approved; a provider prescribes one only when it offers a significant difference for you.

Foundayo vs. Zepbound: your questions

Fair questions about NexLife

Will my price go up with my dose?
No. You pay the same at every dose.
What if I’m not prescribed?
You aren’t charged for medication.
Can I cancel?
Yes, by email. It takes effect 30 days after we receive it. Plans renew until you cancel; our cancellation policy has the details.
Do I need insurance?
No. Pay with an HSA or FSA card, or with Affirm, Klarna or Afterpay at checkout.

What’s the difference between Foundayo and Zepbound?

Foundayo (orforglipron) is a daily pill and Zepbound (tirzepatide) a weekly shot; self-pay, Foundayo is $149 to $349 a month and Zepbound $299 to $699, by dose and refill timing (checked Nov. 15, 2026). Foundayo is approved for weight loss; Zepbound is also approved for moderate to severe obstructive sleep apnea in adults with obesity.

Is Foundayo cheaper than Zepbound?

Yes, self-pay. At LillyDirect, Foundayo is $149 to $299 a month with refills within 45 days (checked Nov. 15, 2026). Zepbound starts at $299; at 7.5 to 15 mg it’s $449 with a refill within 45 days, or $499 to $699 without one. Foundayo’s 2.5 and 5.5 mg prices are reduced through December 31, 2026.

Do you take Foundayo with food?

Either way: its label says one tablet by mouth once a day, with or without food, swallowed whole. Don’t break, crush or chew it, and don’t take more than one tablet a day. Zepbound’s label says once weekly, at any time of day, with or without meals.

Does Medicare cover Foundayo or Zepbound?

Yes, if you have Part D and qualify for Medicare’s GLP-1 Bridge: $50 a month from July 1, 2026 to December 31, 2027, with prior authorization. It covers Foundayo and the Zepbound KwikPen, not Zepbound vials or single-dose pens. It isn’t open to people with type 2 diabetes, moderate-to-severe sleep apnea or fatty liver disease.

Can I switch from Zepbound to Foundayo?

Yes, with a new prescription; your provider decides when and at what dose, since neither label converts one medicine’s doses into the other’s. Don’t take them together: both labels advise against combining either with another GLP-1 medicine. On Medicare’s Bridge, your prior authorization stays valid only if you don’t change GLP-1s.

Is there a tirzepatide pill?

No. The FDA’s Drugs@FDA data list tirzepatide only as injections, Zepbound and Mounjaro (checked November 1, 2026). Foundayo is a pill, but it’s orforglipron, a different medicine. Compounded tablets sold online aren’t FDA-approved and aren’t Foundayo. At NexLife, compounded tirzepatide comes as a weekly shot or a dissolving tablet (ODT); neither is FDA-approved.

Which has more side effects, Foundayo or Zepbound?

Their labels can’t settle it, because the trials were separate. At the top doses, 35% reported nausea on Foundayo (10% on placebo) and 28% on Zepbound (8%). Side effects led 10% on Foundayo and 6.7% on Zepbound to stop (3% and 3.4% on placebo). Compounded tirzepatide wasn’t studied in either trial. Both fall under the FDA’s Nov. 9, 2026, NAION warning for all GLP-1 medicines.

Is Foundayo as effective as Zepbound?

Neither label reports a trial comparing them. In separate 72-week trials, counting everyone who started, average weight loss was 11.1% on Foundayo 17.2 mg and 20.9% on Zepbound 15 mg, against 2.1% and 3.1% on placebo, their labels report. These trials studied orforglipron, the medicine in FDA-approved Foundayo, and FDA-approved Zepbound; compounded tirzepatide wasn’t studied.

How much does a year of Foundayo or Zepbound cost?

Self-pay, a year of Foundayo at 9 mg, or at 14.5 or 17.2 mg refilled within 45 days, is 12 fills of $299: $3,588. Zepbound is 13 fills a year: $5,837 at 7.5 to 15 mg if every refill comes within 45 days, or $6,487 to $9,087 at the regular prices.

How long do Foundayo and Zepbound last in your body?

Foundayo’s half-life is about 29 to 49 hours: it peaks 4 to 8 hours after a dose and reaches a steady level after about a week of daily doses. Zepbound’s half-life is about 5 to 6 days, so a single shot lasts the week.

How much weight do people with type 2 diabetes lose on Foundayo or Zepbound?

Less than people without diabetes, in each label’s second 72-week trial: 9.6% on average on Foundayo 17.2 mg (2.5% on placebo) and 14.7% on Zepbound 15 mg (3.2% on placebo). The trials were separate, not head to head, and compounded tirzepatide wasn’t studied.

Important safety information

Compounded tirzepatide and semaglutide are not FDA-approved, and the FDA hasn’t reviewed them for safety, effectiveness or quality. A provider prescribes them only when they offer a significant difference for you compared with an FDA-approved product. Both medicines may cause thyroid tumors, including cancer: don’t use either if you or a family member has had medullary thyroid carcinoma (MTC), or if you have multiple endocrine neoplasia syndrome type 2 (MEN 2). The most common side effects include nausea, diarrhea, vomiting, constipation and stomach pain.

Read the full safety information

In studies with rodents, both medicines caused thyroid tumors; it isn’t known whether they cause them in people. Tell your provider if you notice a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath. Serious side effects can include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or sulfonylureas), kidney problems from dehydration, severe stomach problems, serious allergic reactions, vision changes in people with type 2 diabetes, and a faster heart rate. The FDA warned on Nov. 9, 2026, that GLP-1 medicines may raise the risk of NAION, a rare eye condition that can cause sudden vision loss in one eye; call your provider right away if that happens (FDA). Tell your care team before any surgery or procedure that uses anesthesia or deep sedation. Don’t combine either medicine with other GLP-1 medicines.

Tirzepatide can make birth control pills less effective: switch to a non-oral method, or add a barrier method such as condoms, for 4 weeks after you start and for 4 weeks after each dose increase. Both medicines may harm an unborn baby. Semaglutide should be stopped at least 2 months before a planned pregnancy. Tell your provider right away if you’re pregnant, planning to be, or breastfeeding.

This is a summary, not the complete safety information. Read the full Prescribing Information for FDA-approved tirzepatide (Zepbound) and semaglutide (Wegovy), and talk with your provider. You can report side effects to the FDA at 1-800-FDA-1088 or fda.gov/medwatch.

† NexLife Price Match Guarantee: for new NexLife members switching from a licensed U.S. telehealth provider or clinic with an active prescription for compounded tirzepatide or semaglutide. We match your regular all-in monthly price there (medication plus any required membership, program or visit fee, on a month-to-month plan); first-month offers, coupons, referral credits and prepaid multi-month rates aren’t matched. Proof from the last 60 days required. A licensed provider must determine that treatment is right for you. Not open to people with Medicare, Medicaid or TRICARE coverage. Full terms.

About NexLife. NexLife is a telehealth and care-coordination platform. Care is delivered through affiliated, physician-owned medical groups, and licensed providers decide whether treatment is right for you. NexLife doesn’t make or compound medication: state-licensed partner pharmacies fill each prescription, and we coordinate the rest. Available only in states where our affiliated providers are licensed.

Who wrote and medically reviewed this page?

Adam Kennah, MDMedical Director, NexLife · Board-certified in emergency medicine (American Board of Emergency Medicine) · NPI 1144260043

Leads the NexLife Medical Team, which writes and medically reviews NexLife’s guides, including this one.

NexLife Medical TeamWrites and updates NexLife’s guides

Labels and Medicare’s rules checked November 1, 2026; Lilly’s prices re-checked Nov. 12, 2026.

  • How we checked. Every clinical fact comes from the prescribing information for Foundayo (revised July 2026) and Zepbound (revised August 2026), read November 15, 2026; trial names and doses come from ClinicalTrials.gov, and approval dates from the FDA’s Drugs@FDA data and its sleep apnea news release. Self-pay prices come from LillyDirect and Lilly’s own terms, re-checked Nov. 12, 2026, and the Bridge’s rules from Medicare.gov and CMS, checked November 1, 2026. We don’t treat separate trials as head to head.
  • Every fact, sourced. Each price and rule links to the page it comes from.
  • How we make money. NexLife is a telehealth and care-coordination platform. We earn revenue when people join NexLife.
  • Corrections, fast. See something wrong or out of date? Email hello@nexlife.us and we’ll fix it.
  • How we work. How we review programs · GLP-1 price index · Is NexLife legit? · States NexLife serves

Paying less elsewhere? We match it.†

You know how the pill and the shot compare. Next: a 3-minute check.

If a weekly shot at one price suits you, a licensed provider reviews your health history and decides if compounded tirzepatide is right for you: $115 a month on the 12-month plan, or $129 month to month.

4.8 out of 5 on Trustpilot, 407 reviews (read Nov. 15, 2026) · Medical director Adam Kennah, MD (NPI 1144260043) · LegitScript-certified

Compounded medications aren’t FDA-approved. A provider prescribes one only when it offers a significant difference for you.

  1. 1
    Tell us about you

    Start online with your health history.

  2. 2
    A licensed provider decides

    Online, following your state’s rules. You’re prescribed only if treatment is right for you.

  3. 3
    We ship it, then stay with you

    Our partner pharmacy usually ships within 1 to 2 business days. Free shipping, and questions come to us 24/7, never to the pharmacy.

Sources

  1. Foundayo (orforglipron) prescribing information, Eli Lilly, revised July 2026. Read November 15, 2026.
  2. Zepbound (tirzepatide) prescribing information, Eli Lilly, revised August 2026. Read November 15, 2026.
  3. ClinicalTrials.gov: NCT05869903 (ATTAIN-1), orforglipron in adults with obesity or overweight. Read October 30, 2026.
  4. ClinicalTrials.gov: NCT04184622 (SURMOUNT-1), tirzepatide in adults with obesity or overweight. Read October 30, 2026.
  5. FDA: Drugs@FDA data for tirzepatide (openFDA). Read November 1, 2026.
  6. FDA news release: FDA Approves First Medication for Obstructive Sleep Apnea (Zepbound). Read November 1, 2026.
  7. LillyDirect: Foundayo self-pay prices. Checked Nov. 15, 2026.
  8. Eli Lilly: Foundayo full terms and conditions (regular self-pay prices, $149 to $349). Read Nov. 15, 2026.
  9. LillyDirect: Zepbound self-pay prices. Checked Nov. 15, 2026.
  10. Eli Lilly: Zepbound full terms and conditions (regular self-pay prices, $299 to $699). Read Nov. 15, 2026.
  11. Eli Lilly: Foundayo coverage, savings and self-pay terms. Checked November 1, 2026.
  12. Eli Lilly: Zepbound savings and self-pay terms. Checked November 15, 2026.
  13. Eli Lilly: Foundayo list price (wholesale acquisition cost) disclosure, $649 per 30 tablets at every strength (April 2026). Read Nov. 15, 2026.
  14. Medicare.gov: Weight loss drugs (the Medicare GLP-1 Bridge). Read November 15, 2026.
  15. CMS: Medicare GLP-1 Bridge. Read November 15, 2026.
  16. NexLife: GLP-1 price index. Compounded prices checked November 15, 2026.
  17. NexLife: pricing, every plan.

Foundayo, Zepbound, KwikPen, Mounjaro and LillyDirect are trademarks of Eli Lilly and Company. NexLife isn’t affiliated with Lilly.